论文部分内容阅读
由欧洲药物化学联合会主办的本次会议,于1990年9月2～7日在耶鲁萨冷举行。登记参加会议的有457人,分别来自以色列、美国、英国、意大利、德国、瑞士、匈牙利和瑞典等31个国家。与组胺和缓激肽作用有关的药物本部分首先由CRGanellin(伦敦大学学院)作了“组胺受体药物的设计”的全文报告,叙述了二条研究路线:一条是对icotidine的结构进行修饰后变成替美斯丁(temelastine),后者具有很强的H_1拮抗活性,并且不通透入脑;另一条是修饰后变成zolantidine,
This meeting, sponsored by the European Federation of Medicinal Chemistry, took place in Yeltsa, from 2 to 7 September 1990. There are 457 registered participants, from 31 countries including Israel, the United States, Britain, Italy, Germany, Switzerland, Hungary and Sweden. Drugs Related to the Role of Histamine and Bradykinin This section first reports the full text of the “Design of Histamine Receptor Drugs” by CR Ganellin (University College London) and describes two lines of research: one is the modification of the structure of icotidine Become temelastine (temelastine), which has a strong H 1 antagonistic activity and does not penetrate the brain; the other is modified into zolantidine,